Ascendis Pharma マネジメント

マネジメント基準チェック /24

Ascendis Pharmaの CEO はJan Mikkelsenで、 Dec2007年に任命され、の在任期間は 17.08年です。は、会社の株式の0.71%を直接所有しており、その価値は€ 55.54M 。経営陣と取締役会の平均在任期間はそれぞれ8.4年と7年です。

主要情報

Jan Mikkelsen

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	17.1yrs
CEOの所有権	0.7%
経営陣の平均在職期間	8.4yrs
取締役会の平均在任期間	7yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Jan Mikkelsen (64 yo)

17.1yrs

在職期間

Mr. Jan Moller Mikkelsen is President, CEO, Member of Executive Board & Executive Director of Ascendis Pharma A/S from December 2007. He joined the Ascendis Pharma A/S in December 2007. He is Chairman of t...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jan Mikkelsen	President	17.1yrs	データなし	0.71% € 55.5m
Scott Smith	CFO, Executive VP & Member of Executive Board	8.4yrs	データなし	0.0067% € 527.0k
Lotte Sonderbjerg	Executive VP	17.1yrs	データなし	0.0031% € 243.9k
Michael Jensen	Executive VP	11.6yrs	データなし	0.0032% € 253.3k
Mads Bodenhoff	Senior VP of Finance & Principal Accounting Officer	less than a year	データなし	データなし
Timothy Lee	Senior Director of Investor Relations	no data	データなし	データなし
Flemming Jensen	Executive Vice President of Product Supply & Quality	9.4yrs	データなし	0.0031% € 243.9k
Kennett Sprogoe	Executive VP and Head of Research & Product Development	9yrs	データなし	0.0048% € 378.7k
Stina Singel	Executive VP & Head of Clinical Development for Oncology	3yrs	データなし	データなし
Joseph Kelly	Head of U.S. Commercial of Endocrinology	2.7yrs	データなし	データなし
Scott Holmes	Head of Global Commercial Strategy of Endocrinology	2.7yrs	データなし	データなし
Camilla Hartvig	Executive VP & Global Chief Commercial Officer	1.6yrs	データなし	データなし

8.4yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: A71の経営陣は経験豊富で経験豊富です（平均在職期間は8.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Jan Mikkelsen	President	17.1yrs	データなし	0.71% € 55.5m
Albert Cha	Independent Chairman	10.2yrs	€139.72k	0.00065% € 51.0k
William Fairey	Independent Director	2.3yrs	€73.01k	0% € 0
Lisa Morrison	Independent Director	7.8yrs	€92.64k	0.00065% € 51.0k
Lars Holtug	Independent Director	6.2yrs	€96.17k	0.0015% € 116.8k
Siham Imani	Independent Director	2.3yrs	€69.48k	0% € 0

7.0yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: A71の取締役会は経験豊富であると考えられます ( 7年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/01/10 06:55
終値	2025/01/10 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Ascendis Pharma A/S 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。21

アナリスト	機関
Tazeen Ahmad	BofA Global Research
Michelle Gilson	Canaccord Genuity
Alethia Young	Cantor Fitzgerald & Co.

Ascendis Pharma マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors

Ascendis Pharma A/S, Annual General Meeting, May 30, 2022

Ascendis Pharma A/S Announces Michael Wolf Jensen Does Not Stand for Re-Election to Its Board

Recent updates

Ascendis Pharma A/S Announces Positive Week 26 Topline Results from New Insights

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Accepts for Supplemental Biologics License Application for TransCon HGH for Adult GHD

Third quarter 2024 earnings released: €1.72 loss per share (vs €2.88 loss in 3Q 2023)

Ascendis Pharma A/S to Report Q3, 2024 Results on Nov 14, 2024

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: €1.91 loss per share (vs €2.16 loss in 2Q 2023)

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

First quarter 2024 earnings released: €2.30 loss per share (vs €1.98 loss in 1Q 2023)

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Full year 2023 earnings released: €8.55 loss per share (vs €10.40 loss in FY 2022)

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

New major risk - Negative shareholders equity

Third quarter 2023 earnings released: €2.88 loss per share (vs €3.03 loss in 3Q 2022)

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Full year 2022 earnings released: €10.40 loss per share (vs €7.00 loss in FY 2021)

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH

Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism

TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Third quarter 2022 earnings released: €3.03 loss per share (vs €1.47 loss in 3Q 2021)

Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT-101, A Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors

Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors

Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial

Ascendis Pharma Submits Transcon™ Pth New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

Second quarter 2022 earnings released: €1.46 loss per share (vs €2.50 loss in 2Q 2021)

Ascendis Pharma A/S Announces Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon HGH in China Consistent

First quarter 2022 earnings released: €2.21 loss per share (vs €1.17 loss in 1Q 2021)

Ascendis Pharma A/S, Annual General Meeting, May 30, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S to Provide an Update on Two of Its Investigational Endocrinology Rare Disease Development Programs

Third quarter 2021 earnings released: €1.47 loss per share (vs €2.31 loss in 3Q 2020)

Ascendis Pharma A/S Announces Mean Bone Mineral Density Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 ß/? Clinical Program

Ascendis Pharma Announces U.S. Food and Drug Administration Approval of SKYTROFA

マネジメント基準チェック /24